News & Research
New studies, trials, regulatory changes and news about the compounds on Amino Reference. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-05.
- EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.
J Hepatol
European liver, diabetes, and obesity societies issued guidance on using semaglutide as MASH-targeted therapy. The GLP1-S page should treat MASH as a human-guidance use and cite this, rather than leaving liver benefit at a lower grade.